All In Biotech

Drug Trial Radar · NCT05732831

Safety and Tolerability of TNG462 in Patients With MTAP-deleted Solid Tumors

A Phase 1/2, Multi-Center, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Anti-tumor Activity of TNG462 as a Single Agent and in Combination in Patients With MTAP-deleted Advanced or Metastatic Solid Tumors

Last checked: Nov 19, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

225

Planned (sponsor's estimate)

Start

May 26, 2023

Primary completion

Jun 2027

Study completion Jun 2028

Sponsor

Lead sponsor
Tango Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Feb 17, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a first in human study in patients with advanced or metastatic solid tumors known to have an MTAP deletion. The first part of the study is an open-label, dose escalation and the second part is an open label dose expansion in specific MTAP-deleted tumor types. The study drug, TNG462, is a selective PRMT5 inhibitor administered orally. The study is planned to treat up to 225 participants.

Conditions

  • Locally Advanced Solid Tumor

Interventions

  • TNG462Drug

    TNG462, a selective PRMT5 inhibitor, will be administered orally

  • PembrolizumabDrug

    An anti PD-1 antibody, will be administered intravenously

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase 1 Maximum Tolerated DoseTime frame: 28 days and 21 days
  2. Phase 1 Dosing ScheduleTime frame: 28 days
  3. Phase 2 Anti-neoplastic ActivityTime frame: 16 weeks and 18 weeks

Locations

26 sites in 3 countries. Site status is shown where the registry gives one.

  • Stanford University

    Palo Alto, California · Recruiting

  • Grand Valley Oncology

    Grand Junction, Colorado · Recruiting

  • Florida Cancer Specialists & Research Institute

    Lake Mary, Florida · Completed

  • Sylvester Comprehensive Cancer Center

    Miami, Florida · Recruiting

  • University Chicago Medicine

    Chicago, Illinois · Recruiting

  • Carle Cancer Center

    Urbana, Illinois · Recruiting

  • Midwestern Regional Medical Center, City of Hope Chicago

    Zion, Illinois · Recruiting

  • Massachusetts General Hospital

    Boston, Massachusetts · Recruiting

  • Dana Farber Cancer Institute

    Boston, Massachusetts · Recruiting

  • Henry Ford Cancer Center

    Detroit, Michigan · Recruiting

  • New York University Langone Health

    New York, New York · Recruiting

  • Sarah Cannon Tennessee Oncology

    Nashville, Tennessee · Recruiting

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Huntsman Cancer Institute, University of Utah

    Salt Lake City, Utah · Recruiting

  • Next Oncology Virginia

    Fairfax, Virginia · Recruiting

  • CHU de Brest

    Brest, France · Recruiting

  • Centre Berard Leon

    Lyon, France · Recruiting

  • Institut de Cancerologie de l'Ouest - Hôpital Saint Herblain - PPDS

    Saint-Herblain, France · Recruiting

  • Institute Gustav Roussy

    Villejuif, France · Recruiting

  • Hospital HM Nou Delfos

    Barcelona, Spain · Recruiting

  • ICO l'Hospitalet - Hospital Duran i Reynals

    Barcelona, Spain · Recruiting

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, Spain · Recruiting

  • Hospital de Sanchinarro

    Madrid, Spain · Recruiting

  • Hospital Universitario Virgen de la Victoria

    Málaga, Spain · Recruiting

  • Hospital Universitario Virgen del Rocio

    Seville, Spain · Recruiting

  • Vall d'Hebron Barcelona Hospital

    Barcelona, Catalonia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.